{"product_id":"cytokeratin-8-antibody-bha17111427","title":"Cytokeratin 8 Antibody","description":"\u003ch2\u003eOverview\u003c\/h2\u003e \u003cp\u003eCytokeratin 8 Antibody is a research-use primary antibody intended for detection of \u003cstrong\u003eCYTOKERATIN\u003c\/strong\u003e in experimental workflows. It is supplied in \u003cstrong\u003ePurified\u003c\/strong\u003e format. Key antibody attributes include Mouse, Monoclonal (mouse origin), clone K8\/383, isotype Mouse IgG1, kappa. Applications listed for this product include FACS, IF, IHC-P, WB. Reported\/annotated localization context: Cytoplasmic. Species reactivity (as provided): Human.\u003c\/p\u003e \u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTarget:\u003c\/strong\u003e CYTOKERATIN (Cytokeratin 8) — selectivity and interpretation should be considered in the context of isoforms, post-translational modifications, and related family members when applicable.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Purified — format can influence background, multiplexing compatibility, and downstream detection strategies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAntibody identity:\u003c\/strong\u003e Mouse, Monoclonal (mouse origin), clone K8\/383, isotype Mouse IgG1, kappa — these attributes help align secondary reagents and controls (e.g., isotype-matched controls) with your assay design.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLocalization:\u003c\/strong\u003e Cytoplasmic — expected subcellular distribution can guide band\/structure interpretation and help flag off-target signal.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct notes (from provided description):\u003c\/strong\u003e Cytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). Cytokeratin 8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibody that recognizes only cytokeratin 8 and 18. Cytokeratin 8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Antibody to Cytokeratin 8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against Cytokeratin 8, 18 and 19). Reportedly, Cytokeratin 8 antibody is useful for the differentiation of lobular (�ring-like, perinuclear�) from ductal (�peripheral-predominant�) carcinoma of the breast.\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWhere multiple assay formats are possible, align the antibody format, host\/isotype, and listed applications with your detection system and controls to support clear interpretation of signal.\u003c\/p\u003e \u003ch2\u003eBiological background\u003c\/h2\u003e \u003cp\u003eIn this catalog, CYTOKERATIN is positioned within \u003cstrong\u003eMolecular \u0026amp; Cellular Biology\u003c\/strong\u003e research contexts. Localization annotations (e.g., Cytoplasmic) can help contextualize expected signal patterns in imaging and fractionation-based readouts. For authoritative gene\/protein nomenclature, domains\/isoforms, and curated functional annotations, consult resources such as UniProt, NCBI Gene, and Ensembl.\u003c\/p\u003e \u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003eHigher-plex and spatially resolved readouts (e.g., multiplex IF\/IHC, spatial omics) are increasing demand for well-characterized primary antibodies with clearly stated host\/isotype and labeling strategies.\u003c\/li\u003e\n\u003cli\u003eGenetic perturbation controls (knockout\/knockdown) and orthogonal measurements (e.g., RNA vs protein) are commonly used to strengthen target attribution when interpreting antibody-derived signals.\u003c\/li\u003e\n\u003cli\u003eReproducibility initiatives emphasize transparent reporting of antibody identity (clone, host, isotype) and experimental context to improve cross-study comparability.\u003c\/li\u003e\n\u003c\/ul\u003e \u003ch2\u003eCommon research applications\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eFACS:\u003c\/strong\u003e interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform\/PTM differences across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIF:\u003c\/strong\u003e interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform\/PTM differences across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIHC-P:\u003c\/strong\u003e interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform\/PTM differences across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWB:\u003c\/strong\u003e interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform\/PTM differences across conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTypical workflow themes:\u003c\/strong\u003e Western blot validation, IHC on FFPE tissue, IF\/ICC localization, Flow cytometry staining, Specificity controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eWorkflow notes:\u003c\/strong\u003e Validate CYTOKERATIN8 by Western blot in cell\/tissue lysates (include controls), Detect CYTOKERATIN8 by IHC in FFPE tissue sections (optimize antigen retrieval + dilution), Detect CYTOKERATIN8 localization by IF\/ICC i…\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eWhen comparing conditions, consistent sample processing and appropriate negative\/positive controls support interpretation of qualitative localization differences and quantitative abundance changes.\u003c\/p\u003e \u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e \u003cul\u003e\n\u003cli\u003eIsoforms and post-translational modifications may shift apparent molecular weight or epitope accessibility, especially across cell states or treatments.\u003c\/li\u003e\n\u003cli\u003eSpecies and tissue context can affect sequence conservation, expression level, and background binding; predicted reactivity should be verified in your sample.\u003c\/li\u003e\n\u003cli\u003eControl concepts include isotype-matched controls, secondary-only controls (for indirect detection), and genetic\/orthogonal controls (e.g., KO\/KD, independent antibodies, or RNA measurements) when feasible.\u003c\/li\u003e\n\u003c\/ul\u003e \u003cp\u003eMonoclonal and polyclonal antibodies can differ in epitope recognition breadth and lot-to-lot characteristics; consider clonality and clone information (when provided) alongside your assay requirements. Conjugated formats may simplify detection but can change background and multiplexing behavior compared with unconjugated primaries.\u003c\/p\u003e \u003c!-- Sources (internal): - UniProt Knowledgebase (UniProtKB) — UniProt Consortium — https:\/\/www.uniprot.org\/ - NCBI Gene — National Center for Biotechnology Information (NCBI) — https:\/\/www.ncbi.nlm.nih.gov\/gene\/ - Ensembl Genome Browser — EMBL-EBI — https:\/\/www.ensembl.org\/ - The Human Protein Atlas — Human Protein Atlas — https:\/\/www.proteinatlas.org\/ - Antibody validation concepts and controls (general guidance) — NIH \/ community resources — https:\/\/www.nih.gov\/ - MIQE\/experimental reporting \u0026 reproducibility (general) — Scientific community guidelines — https:\/\/www.equator-network.org\/ --\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.2 mg\/ml in 1X PBS with 0.1 mg\/ml BSA (US sourced) and 0.05% sodium azide \/ 100 ug","offer_id":53044886372717,"sku":"V2170-100UG","price":559.0,"currency_code":"USD","in_stock":true},{"title":"0.2 mg\/ml in 1X PBS with 0.1 mg\/ml BSA (US sourced) and 0.05% sodium azide \/ 20 ug","offer_id":53044955021677,"sku":"V2170-20UG","price":259.0,"currency_code":"USD","in_stock":true},{"title":"Prediluted in 1X PBS, 0.1 mg\/ml BSA (US sourced), 0.05% sodium azide; *For IHC use only* \/ 7 ml","offer_id":53044955054445,"sku":"V2170IHC-7ML","price":559.0,"currency_code":"USD","in_stock":true},{"title":"1 mg\/ml in 1X PBS; BSA free, sodium azide free \/ 100 ug","offer_id":53044955087213,"sku":"V2170SAF-100UG","price":559.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_a80e4887-02ec-47d4-aaa1-973b14edebba.jpg?v=1782236696","url":"https:\/\/www.ebiohippo.com\/products\/cytokeratin-8-antibody-bha17111427","provider":"BioHippo","version":"1.0","type":"link"}